Chemistry:ZYN-001
From HandWiki
ZYN-001, also known as Δ9-tetrahydrocannabinol D-glyceric acid ester, is a cannabinoid which was under development for the treatment of cancer pain, neuropathic pain, fibromyalgia, and Tourette's syndrome but was never marketed.[1][2][3][4][5] It was formulated as a transdermal patch.[1][3][4] The drug is a synthetic prodrug of Δ9-tetrahydrocannabinol (Δ9-THC) and acts as a cannabinoid CB1 and CB2 receptor agonist.[1][3][4][5] ZYN-001 was under development by Zynerba Pharmaceuticals.[1][2][3][4] It reached phase 1 clinical trials prior to the discontinuation of its development in 2018.[1][2][3][4] The drug was discontinued after it failed to attain target THC blood levels of 5 to 15 ng/mL in a phase 1 trial.[4]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "ZYN 001". 13 October 2023. https://adisinsight.springer.com/drugs/800041360.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on ZYN-001 with Synapse". 27 December 2025. https://synapse.patsnap.com/drug/740ad86f47b14774b318f214c796a7af.
- ↑ 3.0 3.1 3.2 3.3 3.4 "Zynerba Scraps Development of THC Prodrug ZYN001 after Failed Trial". 5 July 2018. https://www.genengnews.com/news/zynerba-scraps-development-of-thc-prodrug-zyn001-after-failed-trial/.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 "Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain". Drugs 81 (13): 1513–1557. September 2021. doi:10.1007/s40265-021-01579-x. PMID 34480749. "The case of Zynerba Pharmaceuticals Inc. (USA), who developed a synthetic d-glyceric acid ester pro-drug of THC administered as a transdermal patch (ZYN001 at 36 mg dose), is indicative of the complexities inherent in properly delivering cannabinoids through the skin [219]. Zynerba conducted Phase I development in the treatment of fibromyalgia and neuropathic pain in Australia. However, development was subsequently discontinued (year 2018) because the study indicated that target blood levels of 5–15 ng/mL THC were not achieved.".
- ↑ 5.0 5.1 Technical Report: Hexahydrocannabinol (HHC) and related substances (Report). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2023. https://www.drugsandalcohol.ie/38606/1/emcdda-technical-report-hhc-and-related-substances.pdf#page=83.
 |  |
